vimarsana.com
Home
Live Updates
Outstanding 5 Year PFS With Lorlatinib in ALK+ NSCLC : vimarsana.com
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Related Keywords
Tennessee ,
United States ,
Boston ,
Massachusetts ,
Australia ,
Chicago ,
Illinois ,
Melbourne ,
Victoria ,
American ,
Jessicaj Lin ,
Davidr Spigel ,
,
European Society For Medical Oncology Virtual Congress ,
Peter Maccallum Cancer Centre ,
Sarah Cannon Research Institute ,
American Society Of Clinical Oncology ,
Harvard Medical School ,
Drug Administration ,
Pfizer ,
Benjamin Solomon ,
Clinical Oncology ,
Lung Medical Oncology ,
Medscape Medical News ,
Medical Oncology Virtual Congress ,
Thoracic Cancers ,
Massachusetts General Hospital ,
Comparator Drug ,
vimarsana.com © 2020. All Rights Reserved.